What happened with RARE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ultragenyx Pharmaceutical serves patients with rare and ultra-rare genetic diseases, often where treatments addressing the underlying disease are lacking. It develops medicines, generally acquiring candidates through academic licenses or pharmaceutical partnerships, and sells approved drugs to wholesalers and pharmacy distributors. Direct drug sales provide slightly more revenue than Crysvita royalties, but Crysvita accounts for most revenue when its direct sales and partner payments are combined. Its other marketed medicines are Dojolvi, Evkeeza and Mepsevii.
Crysvita treats X-linked hypophosphatemia and tumor-induced osteomalacia. Partner Kyowa Kirin (KKC) sells it in the U.S. and Canada and pays Ultragenyx a share of revenue. Ultragenyx sells Crysvita itself in Latin America, paying KKC for supply and royalties. KKC supplies a large share of total revenue and is Crysvita’s sole commercial supplier. Ultragenyx’s U.S. promotion rights are limited to medical geneticists. It has sold its European Crysvita royalty interest and portions of future U.S. and Canadian royalties to investors, so not all related payments remain with the company.
The business depends on finding and diagnosing eligible patients in very small populations and securing insurance or government reimbursement. Product rights also define where it can sell: for example, Regeneron supplies Evkeeza and retains the U.S. market, while Ultragenyx holds rights outside the U.S. Ultragenyx is also developing additional medicines, which need regulatory approval before it can promote them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ultragenyx’s results hinge heavily on Crysvita demand and partner Kyowa Kirin: Crysvita generated 45% of its 2025 revenue, and Kyowa Kirin controls commercialization in several major markets.
Mereo BioPharma and Ultragenyx share setrusumab’s prospects: Ultragenyx leads global development and supplies Mereo, and each pays the other royalties on sales in its territory. Mereo’s sales in the EEA, U.K. and Switzerland would therefore generate royalty income for Ultragenyx.
Ionis Pharmaceuticals competes with Ultragenyx to treat the underlying biology of Angelman syndrome, using drugs that change gene expression through antisense technology. Watch results from Ionis’s obudanersen alongside Ultragenyx’s Phase 3 apazunersen (GTX-102); no drug addressing the disease’s underlying biology is approved.
Ultragenyx depends on Regeneron for Evkeeza supply, paying it for medicine sold outside the U.S., while Regeneron sells Evkeeza in the U.S. Regeneron’s Evkeeza demand among patients with homozygous familial hypercholesterolemia is the relevant read-through, rather than its much broader drug business.
Abeona Therapeutics participates in UX111’s upside after licensing the MPS IIIA gene therapy to Ultragenyx, which now runs the program. After regulatory approval, UX111 sales can trigger payments to Abeona at sales milestones and royalties on net sales.
Denali Therapeutics is developing DNL126 to replace an enzyme in MPS IIIA, competing for the same patients as Ultragenyx’s UX111 gene therapy. DNL126’s clinical results are the comparison to watch in a disease with no approved drug treatment.
Arcturus Therapeutics’ ARCT-810 competes with Ultragenyx’s gene-therapy approach for OTC deficiency, using an mRNA medicine instead. ARCT-810’s Phase 2 results are the relevant comparison for Ultragenyx’s program, not Arcturus’s vaccine sales.
Ultragenyx uses gene-delivery technology licensed from REGENXBIO for its OTC-deficiency and GSDIa programs, owing maintenance fees, milestone payments and royalties; REGENXBIO also develops its own rare-disease gene therapies. Watch the license’s scope and development deadlines: it was terminated for certain indications in November 2025, and Ultragenyx has limited control over the licensed patents.
Beam Therapeutics’ BEAM-301 competes with Ultragenyx’s GSDIa gene-therapy program by editing genes in patients with R83C variants. Watch BEAM-301’s development specifically in that patient group; Beam has no product-sales revenue yet.
Monopar Therapeutics’ ALXN1840 competes for Wilson disease patients with Ultragenyx’s UX701 gene therapy, but uses a once-daily oral copper-binding treatment rather than gene therapy. Watch ALXN1840’s clinical progress as a different treatment option; it remains investigational, not a marketed product.
Regeneron Pharmaceuticals Inc earningsREGN
Regeneron's report can show U.S. demand for Evkeeza, the medicine it supplies to Ultragenyx for sales outside the United States.
Look for Regeneron's disclosures about Evkeeza demand, not results from its much broader drug business. Stronger demand among the relevant patients would point to improving acceptance and a firmer base for Ultragenyx's sales outside the United States; weaker demand would signal a more limited commercial opportunity.
Ultragenyx Pharmaceutical Inc. earningsThis company
Ultragenyx earns from four rare-disease therapies and Crysvita-linked revenue, and its report will show whether patient-driven growth is keeping pace with research and commercial spending.
Read product sales and Crysvita-linked revenue alongside cash used in operations. If both revenue sources grow while operating cash use stays controlled, patient demand is translating into income without spending erasing the gains, supporting the stated 2027 profitability goal. Slower revenue or higher cash use would mean the path still needs more funding.
Mereo BioPharma Group plc earningsMREO
Mereo's report can show setrusumab sales in Europe, which can generate royalties for Ultragenyx, the drug's global development lead and supplier.
Watch Mereo's setrusumab sales in the EEA, U.K. and Switzerland. Higher sales would generate more royalties for Ultragenyx under the arrangement; limited sales would mean limited income from this partnership.
